Incumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on the Brink of Insolvency Act Now to Save AIM Before it is Too Late – The Kellner Group Can Turn AIM Around and Finally Start Creating Value for Stockholders Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Dear AIM Stockholders: Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”), are issuing this open letter to stockholders regarding the 2024 Annual Meeting of Stockholders of AIM ImmunoTech Inc., a Delaware corporation (“AIM” or the “Company”), to solicit your vote to elect each of us to AIM’s Board. We urge you to carefully read our proxy statement and our subsequent communications because they contain important information. Our proxy statement and our other communications are available at https://okapivote.com/AIM/ . Substantial and Immediate Overhaul of the AIM Board is Critical The urgent need for drastic, immediate transformation within the AIM Board is indisputable. Each of the three leading independent proxy advisory firms have acknowledged this in recommending for the election of Mr. Kellner. Two of the three firms acknowledged that the incumbent Board cannot remain in control and recommended for the election of both Mr. Kellner and Mr. Sweeney and against Mr. Equels. 1 Incremental change would be wholly inadequate in this situation. This is not a case of competing visions or differing opinions on AIM’s strategic direction. The incumbent Board has no vision for AIM’s future and no coherent strategy to move the company forward. The scale of value destruction under the incumbent Board’s leadership, combined with their blatant breaches of fiduciary duties (as found by the Delaware Supreme Court), unethical actions, and brazen disregard of stockholders and corporate governance norms, is unprecedented. We urge you to take decisive action by voting on the Gold card for all of the Kellner Group Nominees. The Incumbent Board has Completely Failed and Destroyed Stockholder Value The incumbent Board has controlled AIM for almost nine years since 2016 and failed epically, and dating back even further, Equels (16 years on the Board), Mitchell (26 years on the Board) and Appelrouth (13 years on the Board and consulting) each played a central role in leading AIM down the path of failure and value destruction. 4 When given the opportunity to show they could be responsive to stockholders and fulfill their promise to appoint two new independent directors, the incumbent Board failed yet again. Instead, they appointed Bryan – hand-picked by Equels, without an independent search firm, based solely on a pre-existing relationship with AIM and Equels. This appointment was rubber-stamped by Mitchell and Appelrouth, and Bryan has predictably fallen right in line with their failed leadership. 5 ISS accurately noted that “AIM shareholders did not get an independent voice they were hoping for with Bryan’s appointment.” 6 This is just another example of the incumbent Board’s consistent failure to act in the best interest of stockholders. The following two facts demonstrate beyond question the utter and complete failure of the incumbent Board: AIM’s stock price has declined by over 99% since 2016 when Equels became CEO and Equels, Mitchell and Appelrouth took control of the Board . 7 AIM’s financial condition has deteriorated to the point of functional insolvency, with substantial doubt about its ability to continue as a going concern, insufficient stockholders’ equity to comply with NYSE American listing standards and a lack of viable financing options . 8 The manner in which the incumbent Board brought AIM to this very dire position is even more troubling: They have utterly failed to advance AIM’s clinical program . 9 They have failed to bring a single trial to completion and failed to achieve any FDA approvals. The incumbent Board has consistently neglected to invest in R&D for Company-sponsored clinical trials, and there is no clear strategy or follow-through. Instead, they shift focus aimlessly, chasing fleeting publicity with press releases that are empty of substance, while neglecting to drive trials to completion, secure approvals, or pursue commercialization with any sense of urgency. They delivered zero material process on any of the key clinical indications of Ampligen, failing to advance even a single company-sponsored study to completion. The incumbent Board attempts to hide their failures behind a veil of opacity, but the truth is unmistakable: a stalled program with no direction or visibility or timeline to approvals or revenues. This lack of transparency is, in effect, the only “strategy” the incumbent Board has for its clinical program – and it is failing. They have wasted funds on compensation and unethical litigation to entrench themselves and overseen massive, and increasing, losses . 11 Net losses have totaled over $120 million since 2016 and have accelerated. This is driven by increased G&A, increasing by 2.5x from 2021 to 2023, to support excessive compensation and unethical entrenchment efforts. G&A has been approximately double R&D in recent periods, a totally inappropriate and irresponsible ratio for a clinical stage biotech firm. The incumbent Board, with an average tenure of over 10 years, has not only violated their fiduciary duties but has also shamelessly paid themselves excessive compensation while the stock price has plummeted to less than a quarter. Their failure to act in the best interests of stockholders has directly contributed to the destruction of value, enriching themselves at the expense of AIM’s future. Their corporate governance practices have been abysmal, demonstrating a complete failure of leadership and accountability . 13 These practices include (1) ignoring the will of stockholders by completely disregarding three consecutive failed “say-on-pay” votes, with no meaningful action taken to address the overwhelming disapproval of their compensation practices, (2) making hollow promises to add two new independent directors and review executive compensation, only to betray stockholders by appointing a pre-selected, hand-picked director with deep ties to AIM and Equels, bypassing any independent search process, then engaged the same compensation consultant that had previously recommended excessive pay to conduct a shallow, self-serving review, (3) maintaining a non-stockholder approved poison pill for over 25 years, a blatant disregard for stockholder rights that continues to entrench their control and harm AIM’s long-term value; and (4) launching an aggressive and harmful campaign against stockholders, relentlessly attacking those who seek change and severely damaged the Company financially and strategically and disenfranchised its stockholders. They have violated their fiduciary duties and conducted an egregious self-interested entrenchment campaign that has results in massive waste and destroyed virtually all stockholder value. 16 The Delaware Supreme Court ruled in 2024 that the incumbent Board breached its fiduciary duties. In describing the Board’s adoption of amended bylaws, the court stated that the “ primary purpose was to interfere with Kellner’s nomination notice, reject his nominees, and maintain control ” and that the bylaws were “ product of an improper motive and purpose, which constitutes a breach of the duty of loyalty .” 17 (emphasis added) This illegal behavior by the AIM Board was not an isolated incident. A federal district court in Florida sanctioned AIM and its counsel in 2024 in its Section 13(d) claims against members of the Kellner Group and others – claims that have been dismissed multiple times – for pursuing arguments that were “factually and legally frivolous and advanced for an improper purpose .” 18 The cost of these bad faith actions has been staggering and directly and severely harmed the Company. We estimate the incumbent Board spent between $15 to $20 million in the past two-plus years in pursuit of its self-interested entrenchment campaign . 19 The purpose of this waste was to prevent a meaningful stockholder vote – to deprive stockholders of their basic right to have a say in who represents them on the Board. Now that the incumbent Board has exhausted litigation options to prevent a vote, they have attempted to pad the vote by awarding fully vested shares to executives before the record date, as an advance on future pay – something there is no rational justification for and is a clear continuation of their bad faith and improper purpose. This is shocking and unconscionable behavior – blatantly putting their own self-interest ahead of the Company and its stockholders – to a degree that we have never seen before. The Kellner Group Nominees are the Only Viable Path to Rescue, Rebuild and Revive AIM Collectively, the Kellner Group Nominees will bring a wealth of business, financial, clinical trial, life science and corporate governance experience and much needed credibility to the Board. The incumbent Board does not have the skill set that the Kellner Group does and has no plan to change course . Against all reason, despite overwhelming evidence of their incompetence, and unethical and self-serving actions, they simply ask stockholders to place blind trust in them and their same empty promises that progress is right around the corner. But after nearly nine years of treating AIM like their personal piggy bank, the incumbent Board’s complete and total failure is indisputable. Faced with this harsh reality, they have resorted to attacking us with misleading narratives and outright lies to divert attention from their own disastrous and self-serving record. Here is the undeniable truth: Mr. Kellner and Mr. Deutsch are two of AIM’s largest and long-standing stockholders. We have invested a significant amount in AIM and our sole motivation is to improve performance and create value for all stockholders. We are fully aligned with stockholders and committed to their success . The false narrative being pushed by the incumbent Board – suggesting Mr. Kellner is motivated by personal financial gain to seek reimbursement or will exploit company resources – could not be further from the truth. These claims are completely divorced from reality. Mr. Kellner has spent decades building his business reputation as a trusted investment fiduciary, and this reputation is a testament to his integrity and commitment to the best interests of the investors. All of the Kellner Group Nominees are committed to acting as responsible fiduciaries, focused on financially stabilizing AIM and creating value for all stockholders. This stands in stark contrast to the incumbent Board members, who have egregiously violated their fiduciary duties by prioritizing their own self-interest, resulting in gross waste and destructive value erosion. Similarly, the incumbent Board’s deceitful misrepresentations of settlement discussions is nothing more than bad faith, deliberate attempt to mislead and distort facts. These discussions are a direct result of the incumbent Board’s unlawful entrenchment efforts and involve numerous lawsuits and people unrelated to the Kellner Group. Mr. Kellner remains fully committed to AIM and to using his resources and network to create value if the Kellner Group Nominees are elected . Mr. Kellner and Mr. Sweeney have been transparent about their business relationship – it was disclosed in detail in our proxy statement and Mr. Kellner’s notice. 21 They have long and proven track records of successful investing and running businesses, earning them the trust of their respective investors through exceptional performance and responsible stewardship over many years. Their demonstrated success is a significant strength of our slate and exactly the kind of leadership AIM desperately needs to address its desperate financial situation and secure its successful future. There are absolutely no third parties involved in our efforts that have not been publicly disclosed. None of the participants in our solicitation have any criminal history whatsoever. The incumbent Board’s claims that criminals are involved in the Kellner Group are completely baseless, desperate and outright false . But the incumbent Board needs to look in the mirror – AIM continues to utilize and pay a CRO that was co-founded by a convicted felon, recently convicted of securities fraud related deceiving investors about FDA submissions. This individual was quoted in several AIM press releases in recent years, including promoting clinical progress that did not occur. The parallels are extremely troubling. AIM also resorted to seeking usurious financing from an individual whom the SEC labeled a “recidivist violator of the federal securities laws.” AIM also grossly mischaracterizes Mr. Chioini’s history at Rockwell Medical. Mr. Chioini founded Rockwell and served as CEO for 23 years, and under his leadership became the 2nd largest dialysate supplier in the US with four manufacturing facilities and 330 employees, executed multiple large clinical trials that resulted in multiple FDA approvals, commercialized products, obtained funding through multi-million dollar licensing deals with large pharmaceutical firms and built a business that had a market cap of almost $1.0 billion at its peak. Since Mr. Chioini left Rockwell in 2018, the stock price has declined significantly, losing approximately 95% of its value (Nasdaq: RMTI). AIM also continues to willfully and falsely insist that Mr. Chioini was fired, despite a public record that clearly disproves this claim, including the incumbent Board sitting through a trial that directly dispelled this claim. The truth is that he reached a settlement agreement that resulted in a significant payment to him after a dispute with conflicted board members involving whistleblower retaliation claims made by both him and Rockwell’s former CFO. The incumbent Board’s deliberate misrepresentation of these facts is an outright distortion of the truth, further reflecting their pattern of dishonesty. None of the successes Mr. Chioini achieved at Rockwell have materialized at AIM under the incumbent Board’s leadership, so his proven ability to drive growth, secure FDA approvals, and create value is exactly what AIM urgently needs to turn things around and deliver meaningful results for stockholders. The degree of dishonesty that we have seen from the incumbent Board is staggering . As just one example, they shamelessly attempted to deceive stockholders that the AIM stock price did not decline by over 99% by displaying a 2016 document referencing an unadjusted stock price that did not account for subsequent 1-for-528 reverse stock splits. When we pointed out this blatant misrepresentation, they had the audacity to call us liars. This kind of behavior is not only bizarre, but it shows you can’t believe anything these say – it is like the pot calling the kettle black, and then claiming the sky is not blue. This is their consistent approach – their entire campaign against us revolves around attacking our qualifications, characters, motivations and relationships. But none of it is based in reality whatsoever and it is an intentional, brazen attempt to mislead stockholders and distract from the incumbent Board’s catastrophic failures. The reality is simple: Nothing from the incumbent Board should be trusted . Our Plan will Create Value for Stockholders The Kellner Group is committed to implementing a bold, focused, responsible plan to reverse AIM’s downward trajectory by stabilizing its financial situation, revitalizing its clinical program and restoring real value to stockholders. First and foremost, the Kellner Group will stabilize AIM and ensure it has the financial resources required to continue operations. It is imperative that AIM raise substantial funding in a sustainable way given the catastrophic damage the incumbent Board has inflicted on the Company’s financial health. The Kellner Group Nominees have each successfully raised significant capital, and collectively, have raised over $1.0 billion in investment capital over the years. We have the resources, networks, and credibility to successfully raise the necessary funds and provide the essential runway to finally create value for stockholders and invest in the future of Ampligen. In stark contrast, the incumbent Board simply does not have the credibility, expertise, networks and resources to secure the capital that AIM desperately needs. The incumbent Board’s financing efforts have been disastrous – extremely dilutive and reliant on ATMs, equity lines and excessive warrant coverage. 22 They have failed to secure long-term financing, leaving AIM burdened with massive overhang that has only driven down the stock price. When they have raised capital, they squandered it on self-serving entrenchment efforts, and wasteful G&A and compensation, rather than on meaningful and strategic clinical efforts. 23 The Kellner Group Nominees will draw on their decades of collective experience in generating value for investors, and the trust, credibility and relationships they have built over the years, to attract long-term investment to AIM. We will direct that funding into a sharply focused clinical program. By being transparent with stockholders about AIM’s clinical program and setting clear, achievable goals and timelines, we are confident we can rebuild investor trust of investors and continue to attract capital. The contrast with the incumbent Board could not be more glaring. Once AIM’s financial condition stabilized, the Kellner Group Nominees will take decisive action and implement their plan to revitalize AIM’s clinical program. We will conduct a comprehensive review of the available data on Ampligen, as well as the status of the various ongoing and past trials. This work will begin immediately and will proceed with the urgency it deserves. We will collaborate with AIM’s existing personnel, but will also bring in outside experts in oncology and other relevant fields to ensure AIM’s success. We bring a vast and powerful network of scientific and industry expertise, forged through Mr. Chioini’s extensive career in biotech and pharmaceuticals and Mr. Kellner’s leadership on numerous boards, including the Wisconsin Medical College Board. This network will be instrumental in driving AIM’s turnaround and ensuring its success. Even more compelling, in the past week, we announced the full support of the co-inventor of Ampligen and former CEO of AIM, Dr. Carter, and another former AIM executive, Mr. Springate. Both of these individuals reached out to us due to their deep experience with AIM and Ampligen and their desire to help us deliver the fundamental change AIM so urgently needs. These powerful endorsements underscore the credibility and trust that our team has within the industry and further validates our plan to turn AIM around. This is clear indication that our group has the proven ability to attract the right people, with the right expertise, to collaboratively and effectively work toward turning AIM around and generating meaningful, long-term value for stockholders. The pillars of our clinical program will be as follows: ME/CFS – We will assess whether initiating another Phase 3 trial is viable in the near term, based on the FDA's feedback from 2013. This could potentially accelerate progress and bring us closer to commercialization. Alferon N – We will evaluate the feasibility of restarting production and commercialization of this FDA-approved product, which could generate revenue and strengthen our financial position. Ampligen in Argentina – We will examine whether regulatory and operational efforts can be expedited to launch commercial sales, potentially creating meaningful revenues in the short term. Lastly, but by no means least, we will implement governance reforms and investor outreach that have been completely absent under the incumbent Board. The incumbent Board has not only utterly failed to establish an effective governance structure, but has fostered a toxic, dysfunctional environment marked by unethical conduct, disloyalty to the Company, a constant financial crisis, missed opportunities, and gross mismanagement. Their actions have created a culture of neglect and self-interest that has left AIM in a state of perpetual instability and underperformance. We are committed to making the necessary changes, starting immediately: Board Composition and Independence . We will identify and appoint an additional independent director, with a focus on finding a candidate with no prior history with AIM, with scientific or other relevant expertise, and with a diverse background that reflects a forward-thinking perspective. Compensation Overhaul . We will engage a new, independent compensation consultant to completely restructure AIM’s compensation practices. Our focus will be on slashing guaranteed compensation, reducing executive and director fixed and cash pay, and implementing a performance-driven incentive-based compensation structure with objective performance measures. Poison Pill Review . Review AIM’s poison pill, which has been in effect for almost 25 years without stockholder approval, with consideration of putting it to a stockholder vote if it will be maintained long-term. Investor Communications. Initiate outreach in a transparent manner to stockholders and new investors to tell our story and keep them informed. Unlike the incumbent Board, we will not make empty promises – we will deliver on these critical commitments overhaul the governance structure at AIM to ensure transparency, accountability and long-term stockholder value. The incumbent Board has destroyed stockholder value and imperiled AIM’s future through breaches of its fiduciary duties and bad faith conduct. Stockholders must act now to save AIM before it is too late. We urge stockholders to vote “ FOR ” all four Kellner Group Nominees for urgently needed change. We believe that if the Kellner Group Nominees are elected, AIM’s future will be bright and we stand ready and able to lead a turn around and create value for all stockholders. But if the Kellner Group Nominees do not control the Board, stockholders can expect more of the same value destruction and self-dealing from the incumbent Board and we fear that AIM will have no future at all. Thank you for your support and consideration. The Kellner Group THE KELLNER GROUP URGES ALL STOCKHOLDERS TO VOTE ON THE GOLD PROXY CARD TODAY TO ELECT TED D. KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL SWEENEY If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of the Kellner Group’s proxy materials, please contact Okapi Partners at the phone numbers or email address listed below. Please also visit https://okapivote.com/AIM/ for additional information. Contact: Okapi Partners LLC 1212 Avenue of the Americas, 17th Floor, New York, New York 10036 Stockholders may call toll-free: (844) 343-2621 Banks and brokers call: (212) 297-0720 Email: info@okapipartners.com Important Information and Participants in the Solicitation The Kellner Group has filed a definitive proxy statement and associated GOLD proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified director nominees at the upcoming annual meeting of stockholders of AIM. Details regarding the Kellner Group nominees are included in its proxy statement. THE KELLNER GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Information regarding the identity of participants in the Kellner Group’s solicitation, and their direct or indirect interests, by security holdings or otherwise, is set forth in the Kellner Group’s proxy statement and additional proxy materials filed with the SEC. Stockholders can obtain a copy of the proxy statement, and any amendments or supplements thereto and other documents filed by the Kellner Group with the SEC for no charge at the SEC’s website at www.sec.gov . Copies will also be available at no charge at the following website: https://www.okapivote.com/AIM . Investors can also contact Okapi Partners LLC at the telephone number or email address set for the above. _____________________________________________ 1 The third proxy firm, Glass Lewis, did not meet with us. 2 Permission to use quotations from ISS was neither sought nor obtained. 3 Permission to use quotations from Egan-Jones was neither sought nor obtained. 4 See the definitive proxy statement filed by the Kellner Group with the Securities and Exchange Commission (the “SEC”) on November 6, 2024 (the “Proxy Statement”), pg. 17. 5 See the Proxy Statement, pg. 17. 6 Permission to use quotations from ISS was neither sought nor obtained. 7 See the Proxy Statement, pg. 13. 8 See the Condensed Consolidated Balance Sheets included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 14, 2024 (the “2024 Third Quarter 10-Q”). 9 See the Proxy Statement, pg. 16; see also Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022; the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023; and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024. 10 Permission to use quotations from ISS was neither sought nor obtained. 11 See the Proxy Statement, pg. 17; see also the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 14, 2024; and the Condensed Consolidated Balance Sheets included in the 2024 Third Quarter 10-Q. 12 Permission to use quotations from ISS was neither sought nor obtained. 13 See the Proxy Statement, pgs. 17-18. 14 Permission to use quotations from ISS was neither sought nor obtained. 15 Permission to use quotations from Egan-Jones was neither sought nor obtained. 16 See Proxy Statement, pgs. 8-11. 17 Emphasis added. 18 Emphasis added. 19 Represents Kellner Group estimate based on increase in Company’s G&A expense from 2021 to 2023 and explanations provided as disclosed in AIM’s Annual Reports on Form 10-K for past two years, together with continued elevated G&A expenses in 2024 to date as disclosed AIM’s most recent Quarterly Report on Form 10-Q. 20 Permission to use quotations from Egan-Jones was neither sought nor obtained. 21 See Proxy Statement, pg. 11 and Schedule 13D/A filed by the Kellner Group on September 11, 2024, Exhibit 99.1. With no basis whatsoever, the incumbent Board has tried to claim that this relationship was not fully disclosed. Once proxy advisory firms began recommending for the election of Mr. Kellner and Mr. Sweeney, the incumbent Board leaned into this allegation that was fabricated out of whole cloth in an attempt to question their characters and deceive stockholders. Rather than honestly explain to stockholders why they believe this successful investing relationship would not be beneficial, which they could have done when it was fully disclosed in detail in the notice months ago, the incumbent Board resorts to craven dishonesty and spins false narratives. It is their modus operandi and they have done it throughout this proxy contest and their self-interested entrenchment campaign. 22 See the Proxy Statement, pgs. 15-16. 23 See the Proxy Statement, pgs. 16-18.milyon88 info login registration 。

Lautaro Martinez ends goal drought as Inter keep pressure on Serie A leadersIs he a hero? A killer? Both? About the same time the #FreeLuigi memes featuring the mustachioed plumber from “Super Mario Brothers” mushroomed online, commenters shared memes showing Tony Soprano pronouncing , the man charged with , a hero. There were posts lionizing Mangione’s physique and appearance, the ones speculating about who could play him on “Saturday Night Live,” and the ones denouncing and even threatening people at a Pennsylvania McDonald’s for spotting him and calling police. It was all too much for Pennsylvania's governor, a rising Democrat who was nearly the vice presidential nominee this year. Josh Shapiro — dealing with a case somewhere else that happened to land in his lap — decried what he saw as growing support for “vigilante justice.” The curious case of Brian Thompson and Luigi Mangione captivated and polarized a media-saturated nation. It also offers a glimpse into how, in a connected world, so many different aspects of modern American life can be surreally linked — from public violence to politics, from health care to . It summons a question, too: How can so many people consider someone a hero when the rules that govern American society — the laws — are treating him as the complete opposite? Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson, on Monday at the police station in Altoona, Pa. Writings found in Mangione's possession hinted at a vague hatred of corporate greed and an expression of anger toward “parasitic” health insurance companies. “deny,” “defend” and “depose,” reflecting words used by insurance industry critics, written on them. A number of online posts combine an apparent disdain for health insurers — with no mention of the loss of life. “He took action against private health insurance corporations is what he did. he was a brave italian martyr. in this house, luigi mangione is a hero, end of story!” one anonymous person said in a post on X that has nearly 2 million views. On Monday, Shapiro took issue with comments like those. It was an extraordinary moment that he tumbled into simply because Mangione was apprehended in Pennsylvania. Shapiro's comments — pointed, impassioned and, inevitably, political — yanked the conversation unfolding on so many people's phone screens into real life. “We do not kill people in cold blood to resolve policy differences or express a viewpoint,” the governor said. “In a civil society, we are all less safe when ideologues engage in vigilante justice.” But to hear some of his fellow citizens tell it, that's not the case at all. Like Bonnie and Clyde, John Dillinger, D.B. Cooper and other notorious names from the American past, Mangione is being cast as someone to admire. Luigi Nicholas Mangione is escorted into Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Regina Bateson, an assistant political science professor at the University of Colorado at Boulder, has studied vigilantism, the term to which Shapiro alluded. She doesn’t see this case as a good fit for the word, she says, because the victim wasn’t linked to any specific crime or offense. As she sees it, it's more akin to domestic terrorism. But Bateson views the threats , and ticking up — plus the against President-elect Donald Trump this past summer — as possible signs that personal grievances or political agendas could erupt. “Americans are voicing more support for — or at least understanding of — political violence,” she said. Shapiro praised the police and the people of Blair County, who abided by a 9/11-era dictum of seeing something and saying something. The commenters have Mangione wrong, the governor said: “Hear me on this: He is no hero. The real hero in this story is the person who called 911 at McDonald’s this morning." A person demonstrates Monday near the McDonald's restaurant in Altoona, Pennsylvania, where police earlier in the day arrested Luigi Nicholas Mangione, 26, in the Dec. 4 killing of UnitedHealthcare's CEO in Manhattan. Even shy of supporting violence, there are many instances of people who vent over how health insurers deny claims. Tim Anderson's wife, Mary, dealt with UnitedHealthcare coverage denials before she died from Lou Gehrig’s disease in 2022. “The business model for insurance is don’t pay,” Anderson, 67, of Centerville, Ohio, . The discourse around the killing and Mangione is more than just memes. Conversations about the interconnectedness of various parts of American life are unfolding online as well. One Reddit user said he was banned for three days for supporting Kyle Rittenhouse, after testifying he acted in self-defense when he fatally shot two people in 2020 during protests. “Do you think people are getting banned for supporting Luigi?” the poster wondered. The comments cover a lot of ground. They include people saying the UnitedHealthcare slaying isn't a “right or left issue" and wondering what it would take to get knocked off the platform. “You probably just have to cross the line over into promoting violence,” one commenter wrote. “Not just laughing about how you don’t care about this guy.” Luigi Mangione is taken into the Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Memes and online posts in support of the 26-year-old man, who's charged with killing UnitedHealthcare's CEO, have mushroomed online. Get the latest in local public safety news with this weekly email.SM Supermalls, TikTok Shop redefine retail with She Leads: Fun Beyond ShoppingOutbrain Shareholders Vote to Support Teads Acquisition

A 7-year-old rivalry between tech leaders Elon Musk and Sam Altman over who should run OpenAI and prevent an artificial intelligence "dictatorship" is now heading to a federal judge as Musk seeks to halt the ChatGPT maker's ongoing shift into a for-profit company. Musk, an early OpenAI investor and board member, sued the artificial intelligence company earlier this year alleging it had betrayed its founding aims as a nonprofit research lab benefiting the public good rather than pursuing profits. Musk has since escalated the dispute, adding new claims and asking for a court order that would stop OpenAI’s plans to convert itself into a for-profit business more fully. The world's richest man, whose companies include Tesla, SpaceX and social media platform X, last year started his own rival AI company, xAI. Musk says it faces unfair competition from OpenAI and its close business partner Microsoft, which has supplied the huge computing resources needed to build AI systems such as ChatGPT. “OpenAI and Microsoft together exploiting Musk’s donations so they can build a for-profit monopoly, one now specifically targeting xAI, is just too much,” says Musk's filing that alleges the companies are violating the terms of Musk’s foundational contributions to the charity. OpenAI is filing a response Friday opposing Musk’s requested order, saying it would cripple OpenAI’s business and mission to the advantage of Musk and his own AI company. A hearing is set for January before U.S. District Judge Yvonne Gonzalez Rogers in Oakland. At the heart of the dispute is a 2017 internal power struggle at the fledgling startup that led to Altman becoming OpenAI's CEO. Musk also wanted the job, according to emails revealed as part of the court case, but grew frustrated after two other OpenAI co-founders said he would hold too much power as a major shareholder and chief executive if the startup succeeded in its goal to achieve better-than-human AI known as artificial general intelligence , or AGI. Musk has long voiced concerns about how advanced forms of AI could threaten humanity. “The current structure provides you with a path where you end up with unilateral absolute control over the AGI," said a 2017 email to Musk from co-founders Ilya Sutskever and Greg Brockman. “You stated that you don't want to control the final AGI, but during this negotiation, you've shown to us that absolute control is extremely important to you.” In the same email, titled “Honest Thoughts,” Sutskever and Brockman also voiced concerns about Altman's desire to be CEO and whether he was motivated by “political goals.” Altman eventually succeeded in becoming CEO, and has remained so except for a period last year when he was fired and then reinstated days later after the board that ousted him was replaced. OpenAI published the messages Friday in a blog post meant to show its side of the story, particularly Musk's early support for the idea of making OpenAI a for-profit business so it could raise money for the hardware and computer power that AI needs. It was Musk, through his wealth manager Jared Birchall, who first registered “Open Artificial Technologies Technologies, Inc.”, a public benefit corporation, in September 2017. Then came the “Honest Thoughts” email that Musk described as the “final straw.” “Either go do something on your own or continue with OpenAI as a nonprofit,” Musk wrote back. OpenAI said Musk later proposed merging the startup into Tesla before resigning as the co-chair of OpenAI's board in early 2018. Musk didn't immediately respond to emailed requests for comment sent to his companies Friday. Asked about his frayed relationship with Musk at a New York Times conference last week, Altman said he felt “tremendously sad” but also characterized Musk’s legal fight as one about business competition. “He’s a competitor and we’re doing well,” Altman said. He also said at the conference that he is “not that worried” about the Tesla CEO’s influence with President-elect Donald Trump. OpenAI said Friday that Altman plans to make a $1 million personal donation to Trump’s inauguration fund, joining a number of tech companies and executives who are working to improve their relationships with the incoming administration. —————————— The Associated Press and OpenAI have a licensing and technology agreement allowing OpenAI access to part of the AP’s text archives.

Robots have progressed over the years from clunky hunks of metal to complex, AI-enabled machines capable of running, speaking, and even . But even with all those advances humans still can’t help but place robots in bizarre and uncomfortable situations. This year, researchers took advanced robots and had them clean up , , , and . Two-legged, humanoid robots, which could one day work on factory floors, and . Here are just a few of the oddest things we did to robots this year. Having pets can add a layer of joy to life that’s irreplaceable. That is, except for the one to two times per day that furry new bundle of joy leads you to bend over and scoop excrement off of hot concrete. A Corgi-owning Minnesota man named Caleb Olson is all too familiar with this dilemma and believes he may have created a solution: . He calls his invention the “Poopcopter.” The quadcopter is programmed to fly around a backyard or other predetermined area and use real-time computer vision to scan for signs of poop. Once detected, the “doo doo drone” as Olsen sometimes refers to his invention, will soar down right above its target, rotate around 30 degrees and then use a custom design 3D-printed scooper to grab and remove the waste. In his demonstration, Olson said the packaged poo could then be dispersed in a detected garage area or maybe even on a neighbor’s roof. “Whenever it detects she [Olson’s dog named Twinkie] is pooping it keeps a log of when she poops and stores an image and over time stores a location,” Olsen . “Which is really nice in the winter when snow covers it.” Smoking cigarettes isn’t just rough on the body: they can also make a mess of the planet. In the US in 2021, show there were 9.7 billion cigarette butts discarded on the ground. That’s reportedly around 20% of all litter for the year. Researchers from the Italian Institute of Technology (IIT) in an effort to shrink that growing mountain of butts down. The VERO, or “Vacuum-cleaner Equipped Robot,” has a 3D-printed nozzle equipped on each of its feet which allows it to suck up cigarettes. VERO uses a neural network to interpret visual data from the robot’s onboard cameras. Once it detects a butt, it then quickly runs a calculation to determine the best way to angle itself to vacuum the butts. In theory, a VERO could be deployed on public beaches or other outdoor areas where people tend to flick their spent smokes. Humans don’t have the best track record when it comes to showing kindness to robots. There’s a long history of engineers and everyday people, kicking, , and with cold-hearted detachment. But one researcher from Radboud University Nijmegen named Marieke Wieringa wanted to see if that same dynamic would play out if the robots being tortured could scream out in pain. In an experiment, she has people . In some cases, nothing more would happen but other times the robot would emit a pitiful whimpering sound from its speakers. An artificial pair of eyes would attempt to convey sadness. The human subjects are more likely to feel guilty when the robot cries out. In an additional experiment, Wieringa gave subjects the option of performing a boring task or shaking the robot. The crying robot was a decisive factor in whether people performed the task or not. “Most people had no problem shaking a silent robot, but as soon as the robot began to make pitiful sounds, they chose to do the boring task instead,” Wieringa said in a statement. There’s still no compelling evidence that machines are “conscious” or “sentient” in the way a human is but that hasn’t stopped many from running with the idea. In one of the odder, more esoteric examples of this, artists asked an AI-enabled humanoid robot what type of painting it would hypothetically make in relation to the phrase “AI for Good.” The robot, called Ai-Da, . The robot created multiple portraits which were later called “AI God.” The painter robot was created by Oxford University researchers and the robotics company, Engineered Arts. It captures images using front-facing cameras and then uses onboard graphics algorithms to generate images. A pair or robotic arms controlling paintbrushes then translates those generated images onto paper. Whether you personally appreciate the work or not, someone found it compelling. AI God this year following a bidding war between 27 people. Robots designed to resemble humans already have a tendency to make some people feel uncomfortable. Researchers from the University of Tokyo took that uneasy feeling to the next level, however, by creating lab-grown “skin” bioengineered from human cells. They then . The result is an utterly horrifying, pink, goopy blob. If that wasn’t enough, they also used mechanical actuators to make it look like the pink slop was smiling. Mind-controlling mushrooms might not be as unlikely as it may sound. Earlier this year, researchers from Cornell University and the University of Florence in Italy demonstrated how could cause movements in a starfish shaped connected robot. In a nutshell, the team would shine the mycelium (which naturally doesn’t like light) with flashing UV strobes. The reaction from the fungus to the light would then trigger the squishy robot to move its leg. The mycelium, in other words, was controlling the robot’s “brain.” In practical terms, researchers believe these kinds of robotic biohybrids could one day analyze agricultural fields on their own to monitor for potentially harmful changes in soil chemistry. Human-looking bipedal robots are becoming increasingly popular, with several companies including Tesla collectively spending billions to make them a reality. But it’s still not entirely clear what they will end up doing. Supporters say they could work in factories, perform dangerous tasks, or even do your laundry. One humanoid robot company called Unitree recently showed off different use cases: . In a , the company showed its oddly flexible ‘G1 Humanoid Agent’ contouring itself into pretzel shapes and performing a variety of seemingly useful and semi-useful tasks. At one point, a researcher straps on a red boxing glove and gives the robot a few hefty jabs to the chest. It stumbles but never falls. Robots are getting . But just like human doctors, robots also can’t just operate on humans without practice. In an odd example this year, scientists taught this surgical robot to use a small pair of tweezer-like grabbers to . If that doesn’t sound all that impressive on its own, consider that the robots were able to perform this test surgery after simply analyzing prior video footage from real medical experts. The researchers behind the robot were surprised at just how well their training method, which is similar to the process powering large language models like ChatGPT, worked in practice. “All we need is image input and then this AI system finds the right action,” postdoctoral researcher Ji Woong Kim said. “We find that even with a few hundred demos, the model is able to learn the procedure and generalize new environments it hasn’t encountered.” Researchers from Google DeepMind actually realized the dream of many sports-living kids: . Using deep reinforcement learning, the researchers were able to train a pair of robots in simulations on soccer-related training data. This process is similar to the way DeepMind previously trained AI models to beat humans at games like Chess, Go, and . But unlike those cases, the researchers now had to apply those learning to a physical robot body. It took some time but eventually, the pair of robots were able to dribble, defend, and even shoot goals though not without the occasional tumble here and there. The Large Hadron Collider in Geneva is the source of important scientific discoveries but it’s also exceptionally dangerous. The powerful particle accelerator smashes protons at nearly the speed of light which results in radiation. That radiation is harmful to humans, but not to robots. Scientists at the European Organization for Nuclear Research (CERN) realized that and specifically designed to crawl and scurry its way through otherwise impenetrable areas of the facility. Once inside, the Good Boy could autonomously patrol and monitor for signs of fires or other potentially dangerous hazards. No one has made a bigger name for themselves by than Boston Dynamics. The company repeated that trend this year with its new, smaller Atlas humanoid robot. In a demonstration of its practical abilities this year, the company released a video of it grabbing and moving engine covers, all autonomous. And because it was Halloween, it did all this while wearing a hot dog outfit. Just a month later Atlas made another festive appearance, . In that video, Atlas performed a slightly terrifying backflip reminiscent of its older, beefier predecessor. It’s unclear what the practical application of robot backflips is, but they certainly are memorable.

Ethan Taylor scores 21 as Air Force takes down Mercyhurst 82-48

Shoppers rush to buy 'timeless and elegant' watch that doesn't need batteries as ultimate Christmas giftSaturday, December 21, 2024 Lufthansa Group is advancing its commitment to sustainability and efficiency with an expanded order for Airbus A350-1000 aircraft. Increasing its firm commitment from 10 to 15 jets, the Group plans to integrate these state-of-the-art planes into its fleet between 2028 and 2030. This $2 billion USD investment underscores Lufthansa’s dedication to fleet modernization and environmental responsibility. Upon delivery, the airline will operate a total of 75 A350 aircraft, comprising 60 A350-900s and 15 A350-1000s, solidifying its position as one of the largest A350 customers worldwide. The A350-1000’s advanced technology reduces fuel consumption and emissions by 25% compared to older models, supporting Lufthansa’s goal of achieving net-zero emissions by 2050. Beyond sustainability, the A350-1000 is designed to enhance the passenger experience. With spacious cabins, advanced air filtration systems, and ergonomic seating across all classes, the aircraft offers travelers a quieter and more comfortable journey. This fleet expansion not only reflects Lufthansa Group’s operational ambitions but also its vision to lead the aviation industry into a sustainable future. By investing in cutting-edge technology, Lufthansa is setting new benchmarks for innovation and environmentally conscious air travel while maintaining its role as a global connector of people and destinations. Carsten Spohr , Chairman of the Executive Board and CEO of Deutsche Lufthansa AG: “Today’s order underscores our great confidence in our long-standing, close and successful partnership with Airbus. With the state-of-the-art A350 long-haul jets, we are accelerating the largest fleet modernization the Group has done so far. We are investing more than ever before to make air transport more sustainable, to achieve our CO2 reduction targets and at the same time offer our customers the highest level of comfort with a first-class travel experience. Including today’s order, the Lufthansa Group has ordered 770 aircraft from Airbus throughout its history and is proud to be the Airbus’ largest customer worldwide. With the upcoming integration of ITA Airways in January, the Airbus fleet of Lufthansa Group Airlines will grow by another 100 short- and long-haul aircraft.” New Aircraft: Key to Lufthansa Group’s CO2 Reduction Strategy The Lufthansa Group, with a current fleet of approximately 740 commercial aircraft, is implementing a long-term fleet strategy centered on premium quality, cost efficiency, and significant reductions in emissions. Following its latest order, the Group has around 250 new fuel-efficient aircraft on its order list, including 100 state-of-the-art long-haul jets. These advanced aircraft are set to replace less efficient, four-engine models such as the Boeing 747-400, Airbus A340-600, and Airbus A340-300, which are being gradually phased out. The new fleet additions are designed to consume up to 35% less fuel compared to their predecessors, resulting in significantly lower CO2 emissions. These measures are part of Lufthansa’s broader environmental commitment to halve its net CO2 emissions by 2030 compared to 2019 levels through reduction and compensation efforts, and to achieve carbon neutrality by 2050. Among the highlights of its fleet modernization is the Airbus A350-1000, ten of which were ordered in March 2023. Deliveries for this fuel-efficient aircraft, which is 73.8 meters long and offers 15% more capacity than the A350-900, are scheduled to begin in April 2026. The new aircraft will play a pivotal role in achieving Lufthansa’s ambitious sustainability goals.In a cavernous warehouse north of New York City, a 16-foot robot outfitted with a cutting tool etched intricate grooves into a faceless marble head atop an alien-like torso. Water sprayed into the air as an image created with artificial intelligence entered the physical world. In February, during a three-month stint as OpenAI’s first artist in residence, Alexander Reben gained early access to the startup’s Sora text-to-video tool, which instantly generates videos up to a minute in length from written or spoken prompts. Reben, a technologist trained at the Massachusetts Institute of Technology, used Nvidia’s neural radiance field technology to turn Sora’s AI-generated imagery into 3D models. The cutting tool, run by a small company called Monumental Labs, turned one of those into a 4-foot-tall sculpture carved from white Italian marble veined with black and gray. While many artists view AI as a threat to their livelihoods, Reben, whose residency ended in April, embraces it as a collaborator. “I got a closer view of how innovation happens within an AI company, and got a better idea of why it’s important to push the edges and try new things,” Reben, 39, said. Toward the end of the residency, he focused on a prototype system that turned photos of real objects into AI-generated images, poems and even short, satirical blurbs. His setup consisted of his phone, a Fujifilm Instax photo printer and another printer that spit out receipts and labels. A web browser-based system combined Reben’s code with a version of the large language model that powers ChatGPT. The “conceptual camera,” whose interface appeared on Reben’s phone screen, had 15 “modes.” One of them, which Reben calls “Silly AI Label Maker,” assigns a name to any item pictured. When he snapped an image of a yellow zinnia, for example, out popped a label designating the flower a “sunny puffball.” The vase containing the flower got a new name, too: “sunflower sipper.” Sunglasses became “shady peepers.” To demonstrate his conceptual camera, Reben held his phone above a rudimentary sketch of a face, a lone tear falling from each eye, alongside a shape that passed for a tree. Almost as quickly as he took the photo, an image sprang from a hand-held printer. The setup turned the drawing into a bizarre, AI-generated picture that blended the face and the tree into a tearful, ghoulish man with a neck and shoulders that looked like they had been carved from wood. OpenAI, which is based in San Francisco, says artists like Reben help it understand the potential of its AI tools. His projects “showed our technology in a new light, inspiring our teams to see the creative possibilities of what we’re building,” a spokesperson for the company said in an email. But Hugh Leeman, an art lecturer at universities such as Duke, Colorado State and Johns Hopkins, wonders if the residency is just a marketing move to appease artists who worry their work is being used to train AI systems without permission, payment or credit. Some are concerned that AI could alter the very nature of creativity. “From a company standpoint, they’re getting out ahead of the curve here,” Leeman said. “This is a mechanism of saying: ‘Look, we’ve always loved artists. In fact, we’ve worked with artists.’” But he is a fan of Reben. Leeman started researching his work after seeing it last year at the Crocker Art Museum in Sacramento, California. Leeman was most struck by the cheeky mischief — like the AI-generated snubs of the artist’s show that rotated on a wall display, declaring it, among other insults, a “masterstroke of blandness.” “It was both criticizing AI and criticizing him for using it,” Leeman said. “I thought, what a beautiful sense of humor and self-awareness on this that is very needed in the art world.” That humor comes through in Reben’s camera. One of its modes takes images and gives them an absurd twist: Imagine a battalion of tiny toy soldiers climbing a scone as if it were a hilly battlefield. Reben took a photo of sunglasses sitting on a table at his home in Berkeley, California. (He had set out those and other random objects for his demonstration.) The camera produced eight paragraphs under the headline “Local Sunglasses File Restraining Order Against Unrelenting Sun.” The overworked glasses, according to the text, are simply asking for more temperate working conditions: “a few clouds” now and then, or an “occasional overcast day.” “The sun has yet to respond to the allegations,” the passage continues. “Legal experts speculate that the solar defendant might struggle to appear in court given its 93-million-mile commute and busy schedule keeping the solar system in order.” Reben’s works, including some created during the OpenAI residency, are on view at the Charlie James Gallery in Los Angeles. In December, they will appear as part of an exhibit by the Bitforms Gallery at Untitled Art, a contemporary art fair in Miami Beach. Reben said that he understood and empathized with the concerns roiling the artist community as AI evolved, but that new technologies always face growing pains. “There are different types of art,” he said, “and different reasons that art exists.” This article originally appeared in .

CHARLOTTE, N.C. (AP) — Patrick Mahomes continues to build great chemistry with his tight end — just not the one you might think. Mahomes threw two touchdown passes to Noah Gray for the second straight week as the Kansas City Chiefs held off the Carolina Panthers 30-27 on Sunday. A week after losing at Buffalo, the two-time defending Super Bowl champion Chiefs (10-1) maintained their position atop the AFC. Mahomes completed a 35-yard touchdown strike to Gray on the game’s opening possession and found him again for an 11-yard TD in the second quarter. Gray has four touchdown catches in the last two weeks — twice as many as nine-time Pro Bowler Travis Kelce has all season — and has become a weapon in the passing game for the Chiefs, who lost top wide receiver Rashee Rice to a season-ending knee injury in Week 4. Kelce was still a factor Sunday with a team-high six catches for 62 yards, although the four-time All-Pro looked dejected after dropping one easy pass. Kelce has 62 receptions for 507 yards this season, while Gray has 26 catches for 249 yards. But Gray's development is a good sign for the Chiefs — and he's on the same page with Mahomes. On his second TD, Gray said Mahomes “gave me the answer to the test there” before the play. “He told me what coverage it was pre-snap," said Gray, who had four receptions for 66 yards. “That’s just the blessing you have of playing with a quarterback like that. Offensive line did a great job blocking that up and the receivers did a great job running their routes to pop me open. Really just a group effort right there on that touchdown.” Gray said that's nothing new. “Pat’s preparation, his leadership is just something that I’m fortunate enough to play alongside,” Gray said. "I love it. It gets me motivated every time we go out there for a long drive. Having a leader like that, that prepares every single week in-and out, knows defenses, knows the game plans. “I’m just fortunate enough to play alongside a guy like that.” Mahomes completed 27 of 37 passes for 269 yards and three TDs, and he knew what to do on the second TD to Gray. “It's not just me, it's the quarterback coaches and the players, we go through certain checks you get to versus certain coverages,” Mahomes said. “I was able to see by the way they lined up they were getting into their cover-zero look. I alerted the guys to make sure they saw what I saw and I gave the check at the line of scrimmage.” AP NFL: https://apnews.com/hub/nfl

US finally breaks silence over China’s sixth-generation fighter jet J-36, it could tilt power balance in favour of...

A trio of running backs recorded touchdowns to help Nebraska hold off Boston College's late rally for a 20-15 win in the Pinstripe Bowl on a rainy Saturday afternoon in Bronx, N.Y. New York native Rahmir Johnson scored the Cornhuskers' opening touchdown to highlight his 60-yard performance on 10 carries. His 11-yard run on fourth-and-1 before the two-minute timeout iced the game, lifting Nebraska (7-6) to its first winning season since 2016. Kwinten Ives also ran for a score and Emmett Johnson (team-high 68 rushing yards on 14 carries) caught one from freshman quarterback Dylan Raiola, who was 23 of 31 for 228 yards, one touchdown and one interception on the day. Nebraska coach Matt Rhule noted that Rahmir Johnson, the game's most valuable player, was playing after his mother died in November. "He loved his mother," Rhule said. "He lost his mother. He cares about this team. I think this is a fitting end for him. I hope he wears his pads home on the subway and goes to his apartment, takes that MVP trophy and takes it out tonight somewhere." Nebraska had a 20-2 lead before allowing its first touchdown with 6:11 left in regulation. Boston College (7-6) forced two first-half turnovers and finished five of its first seven drives inside the opposing 35-yard line, but the Eagles went 0-for-4 on fourth downs until Turbo Richard's 1-yard touchdown run in the fourth quarter. Nebraska's first two punts turned into touchdowns for the Eagles, with the second being blocked and returned to the 2-yard line ahead of a Jordan McDonald score with 4:18 remaining. "Yeah, these guys fought hard," Boston College coach Bill O'Brien said. "We have a tough football team. They never quit. That's what BC is all about." Grayson James quarterbacked the Eagles, going 25 of 40 for a season-high 296 yards. He also rushed for 22. Lewis Bond made six catches for 94 yards. Jahmal Banks was Raiola's leading target, making four catches for 79 yards. After big plays went by the boards for both teams on their opening series, Raiola sent Nebraska on a 15-play, 75-yard drive to the opening touchdown four seconds into the second quarter. Following a third-down conversion in the red zone, Rahmir Johnson scored on a 4-yard run before John Hohl's PAT made it 7-0. After Boston College was unable to convert on Josiah Griffin's recovery of an Emmett Johnson fumble, an ensuing fourth-down penalty gave Nebraska new life and the Cornhuskers turned it into Ives' 2-yard score with 3:39 before halftime. Ashton McShane's 88-yard blocked PAT return got the Eagles on the board at 13-2, though. Nebraska's first drive out of halftime included two fakes from punter/holder Brian Buschini, including a successful fake field goal. On the following series, Raiola's 13-yard pass to Emmett Johnson out of the backfield resulted in a 20-2 lead with 3:02 left in the third. "Dylan, for us to have a chance, you're going to have to play well," Rhule said. "Everyone else has to do the same thing, but that last drive, for us to win the game, he had to go play well." Richard punched in the first Boston College touchdown. James' two-point conversion pass attempt failed. Buschini's second punt was blocked by Victor Nelson Jr. and returned to the 2-yard line by Omar Thornton, setting up McDonald's run and a Liam Connor PAT. "I think we have a bright future at Boston College," O'Brien said. "Today didn't go the way we wanted it to go, but today could have got really ugly. It really could have because Nebraska, they did a good job. But our guys hung in there. They fought, and I have nothing but good things -- very proud of our effort today." --Field Level Media

Chubb Ltd. stock rises Friday, still underperforms marketHow secure is M’sia’s energy value chain?